Abstract:Objective High tumor mutational burden (TMB) is a promising biomarker for patients with immunotherapy in certain types of solid tumors. This article focuses on exploring possible universally optimal cutoffs of TMB for predicting immune checkpoint inhibitors (ICIs) response and prognosis for eight types of cancers. Methods The present study collected eight types of tumors including 2767 patients receiving immune checkpoint inhibitors (ICIs) treatment and 14862 patients without ICI treatment. We tried to explore optimal cutoffs of TMB in each type of tumor via selecting several possible cutoffs of TMB including 10mut/Mb, top 10%, 20%, and 30% of TMB within each histology. Results We found that there was a significant difference in TMB values between ICI-treated and non-ICI-treated groups. The cutoff of TMB appropriate for predicting response rates, progression rates, and survival rates was varied in ICI therapy patients. Moreover, the optimal cutoff of TMB for predicting progression-free survival and overall survival in different types of the tumor was also quietly different. Conclusion Our current study suggested that TMB predicts prognosis and responses to ICI treatment in a cancer-dependent manner. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research was supported by the National Natural Science Foundation of China (No.82273328), and the Translational Medicine Research Fund of Zhongnan Hospital of Wuhan University (ZLYNXM202011). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes * TMB : Tumor mutational burden ICIs : Immune checkpoint inhibitors PD-1 : Programmed death 1 PD-L1 : Ligand of the PD-1 axis CTLA4 : Cytotoxic T lymphocyte antigen 4 FDA : United States Food and Drug Administration PFS : Progression-free survival OS : Overall survival MSI-H : high microsatellite instability

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy

Tumor Mutation Burden Analysis in a 5,660 Cancer Patient Cohort Reveals Cancer Type-Specific Mechanisms for High Mutation Burden.

Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data

Abstract 1614: the Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

The association between tumor mutational burden and prognosis is dependent on treatment context

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

High Tumor Mutation Burden Predicts Better Efficacy of Immunotherapy: a Pooled Analysis of 103078 Cancer Patients.

Tumor Mutational Burden is a Determinant of Immune-Mediated Survival in Breast Cancer

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent manner

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Therapeutic Guidance of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-analysis